GlobeNewswire

Infomedia goes global with acquisition of Opoint Technology

Dela

COPENHAGEN, Denmark, Feb. 20, 2018 (GLOBE NEWSWIRE) -- The Copenhagen based, Nordic media intelligence company, Infomedia acquires Norwegian Opoint Technology from M-brain. The transfer includes Opoint's leading global web-crawling technology for online media, the business of web-crawling services for +70 international media monitors and key personnel in Oslo and Chennai.   

Continued international growth in insights, global content and social media
Over the last couple of years, Infomedia had begun a journey towards becoming a Nordic player. The company invested heavily in new technology, data science, insight products and services and new partnerships.  

"We transformed Infomedia from a 'traditional' media monitor to becoming a full-scale media intelligence company with strong insights capabilities and leading solutions within all aspects of the media space, including print, online, broadcast and social media," says Infomedia's CEO, Thomas Vejlemand.

He continues; "The acquisition marks yet another milestone for Infomedia. We are now able to provide global online media content and a strong web-crawling technology for new digital products. This goes very well in hand with the partnerships with Talkwalker and Hootsuite for social media listening and engagement. We also strengthen our position in the global media monitoring space by having an even stronger partner channel with customers from US, to Europe and Asia," says Vejlemand

Developing a global strong hold in online media content
The acquisition delivers on many fronts. "We believe in continued growth in web-crawling services for the media intelligence space - both by driving the solution to new customers, but also by adding new services on top of the current crawling, feeds and platform," says Vejlemand. He continues, "We see new opportunities with other technology platforms and industries, where high-quality global media content could make an impact, i.e. Social media-platforms, CRM, ERP, CMS, e-commerce. Improved insights in media content could be one differentiating factor for many platforms, and we want to take Opoint web data and technology to those new levels in the global tech-space."

Creating new solutions for the Nordic customer base
The acquisition of Opoint Technology does not change the current Nordic collaboration between Infomedia and M-brain under the partnership "MIA - Media Intelligence Alliance". The two Nordic players will still operate jointly on Nordic print media solutions, but Infomedia is looking to expand their current customer offering for digital media in the Nordics and international media intelligence space.

"Our Nordic clients will now have access to global media content directly from Infomedia including a +5 billion web articles archive, which is part of the acquisition," says Vejlemand. He continues, "We are seeing obvious trends for greater demands for media insights beyond the PR and communication departments, and with Opoint, we will look towards developing new solutions towards marketing, sales & service, top management and HR."

Welcoming a strong team with focus on future development
Under Infomedia, Opoint Technology will continue its 25 people operations across Norway and India, still with Jon Anders Tangnes in charge of customer relations and Rune Kleveland heading the continued development of the web-crawler. 

"Over the last several years, Infomedia has become a strong voice in the global media intelligence space with many interesting cases and an admirable international mindset from a strong Nordic position. We look forward to become a part of a company that will focus on further development of our technology," says Jon Anders Tangnes, COO in Opoint Technology.

The acquisition of Opoint was finalized on February 15th 2018.

Press contact:
Tine Duelund Schou, Head of Communications
+45 2636 4307
Tine.d.schou@infomedia.dk

About Infomedia 
Infomedia A/S is a +20 MEURO media intelligence company, who is leading in media monitoring and media analysis across print, web, broadcast and social in Denmark and the Nordics. The company is located in Copenhagen and has offices in Oslo and Stockholm, a development team in St. Petersbourg and a production team in Chennai, India. The company was established in 2003 and is owned 50/50 by the two media companies JP/Politiken and Berlingske Media.  

Chairman of the board:  Stig Ørskov, JP/Politikens Hus, CEO: Thomas Vejlemand, Infomedia A/S

About OpointTechnology
OpointTechnology is a business unit previously owned by M-Brain. The business unit cowers a leading web-crawler platform for global online media monitoring including an international business of +70 media monitors and employees in Norway and India.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Infomedia A/S via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum